Pain syndromes in haematological malignancies: An overview

Hematology Journal

Volumn 5, Issue 4, 2004, Pages 293-303

  Niscola, Pasquale ^a,h   Arcuri, Edoardo ^b   Giovannini, Marco ^c   Scaramucci, Laura ^a   Romani, Claudio ^d   Palombi, Francesca ^e   Trapè, Giulio ^f   Morabito, Fortunato ^g  

^a ASL Viterbo   (Italy)

^b IRCSS 'San Raffaele' Institute   (Italy)

^c Umberto I Hospital   (Italy)

^d Ospedale Oncologico A Businco   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h Montefiascone Hospital   (Italy)

Author keywords

Bone pain; Hematological malignancies; Hematology; Leukemia; Pain

Indexed keywords

AMIFOSTINE; AMITRIPTYLINE; ANALGESIC AGENT; BENZODIAZEPINE; BUPRENORPHINE; CHLORHEXIDINE; CLARITHROMYCIN; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; FENTANYL; GABAPENTIN; GLUTAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KETAMINE; LEVORPHANOL; LEXIDRONAM SAMARIUM SM 153; METHADONE; MIDAZOLAM; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; TRAMADOL; VINCA ALKALOID; ZOLEDRONIC ACID;

ANALGESIA; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BONE MARROW TRANSPLANTATION; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER THERAPY; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERALGESIA; LUMBAR PUNCTURE; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL SPECIALIST; MOUTH HYGIENE; MUCOSA INFLAMMATION; NEUROPATHIC PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; RADIATION DOSE FRACTIONATION; RATING SCALE; REVIEW; STOMATITIS; WORLD HEALTH ORGANIZATION;

ANALGESIA; BONE AND BONES; BONE MARROW; HEMATOLOGIC NEOPLASMS; HUMANS; PAIN; PAIN MEASUREMENT;

EID: 4544278594     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200530     Document Type: Review

References (153)

1. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology (Huntingt) 2001; 15: 1627-1640, 1642.
2. Caraceni A. Clinicopathologic correlates of common cancer pain syndromes. Hematol Oncol Clin North Am 1996; 10: 57-78.
3. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82: 263-274.
4. Ripamonti C, Bruera E. Pain and symptom management in palliative care. Cancer Control 1996; 3: 204-213.
5. Holdsworth MT, Raisch DW, Winter SS, Frost JD, Moro MA, Doran NH et al. Pain and distress from bone marrow aspirations and lumbar punctures. Ann Pharmacother 2003; 37: 17-22.
6. Chordas C. Post-dural puncture headache and other complications after lumbar puncture. J Pediatr Oncol Nurs 2001; 18: 244-259.
7. Mattano LA, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Study Group. J Clin Oncol 2000; 18: 3262-3272.
8. Weng HR, Cordella JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 2003; 103: 131-138.
9. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-2205.
10. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001; 27 (Suppl 2): S3-S11.
11. Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003; 98: 406-412.
12. Portenoy RK. Cancer pain: epidemiology and syndromes. Cancer 1989; 63: 2298-2307.
13. Twycross R, Harcourt J, Bergl S. A survey of pain in patients with advanced cancer. J Pain Symptom Manage 1996; 12: 273-282.
14. Haddy TB, Mosher RB, Reaman GH. Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist 2001; 6: 278-285.
15. Strass A, Su JT, Kimball Dal ton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 2001; 19: 3066-3072.
16. Aricò M, Boccalatte MF, Silvestri D, Barisone E, Messina C, Chiesa R. Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 2003; 88: 747-753.
17. Bataille R, Harousseau J-L. Multiple myeloma. N Engl J Med 1997; 336: 1657-1664.
18. Paydas S, Ergin M, Baslamisli F, Yavuz S, Zorludemir S, Sahin B. Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol 2002; 70: 300-305.
19. Forrest DL, Mack BJ, Nevill TJ et al. Bone marrow necrosis in adult acute leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 38: 627-632.
20. Gnann JW, Whitley RJ. Herpes Zoster. N Engl J Med 2002; 347: 340-346.
21. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. New Engl J Med 1997; 337: 898.
22. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338: 1601-1607.
23. Jonsson OG, Sartain P, Ducore JM, Buchanan GR. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes. J Pediatr 1990; 117: 233-237.
24. Niscola P, Cartoni C, Arcuri E, Giovannini M, Romani C, Moleti ML et al. Epidemiologia e fisiopatogenesi del dolore nelle neoplasie ematologiche in fase avanzata. Riv Ital Cure Palliat 2000; 2: 157-161.
25. Bauduer F, Capdupuy C, Renoux NL Characteristics of deaths in a department of oncohaematology within a general hospital. A study of 81 cases. Support Care Cancer 2000; 8 (4): 302-306.
26. Novik A, Manikhas G. Comparison of symptom severity and prevalence between hematological malignancies and solid tumors among Russian oncology patients. Proceedings of the Forty-fourth annual meeting of the American Society of Hematology, American Society of Hematology, Pennsylvania. Blood 2002; 100 (Suppl, Part 1): 387b.
27. Stalfelt AM, Brodin H, Pettersson S, Eklof A. The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain. Leuk Res 2003; 27: 481-488.
28. Hongo T, Watanabe C, Okada S, Inoue N, Yajima S, Fujii Y, Ohzeki T. Analysis of the circumstances at the end of life in children with cancer: Symptoms, suffering and acceptance. Pediatr Int 2003; 45: 60-64.
29. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002; 113: 155-166.
30. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410: 471-475.
31. Ma W, Eisenach JC. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 2002; 15: 1037-1047.
32. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of Prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41: 299-332.
33. Woolf CJ, Thompson SW. The induction and maintenance of central sensitisation is dependent on N-methyl-D-aspartate acid receptor activation; implications for the treatment of post-injury hyper-sensitivity states. Pain 1991; 44: 293-299.
34. Banati RB. Brain plasticity and microglia: is transsynaptic glial activation in the thalamus after limb denervation linked to cortical plasticity and central sensitisation? J Physiol Paris 2002; 96: 289-299.
35. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003; 97 (Suppl): 866-873.
36. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 2003; 104: 550-558.
37. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 2002; 29 (Suppl 17): 11-16.
38. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98: 11581-11586.
39. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278-290.
40. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18.
41. Ripamonti C, Fulfaro F. Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 2000; 4: 187-196.
42. Terpos E, Apperley JF, Samson D, Rahemtulla A. Management of multiple myeloma. Haema 2002; 5: 24-38.
43. Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E et al. Infection - an underappreciated cause of bone pain in multiple myeloma. Br J Haematol 2003; 120: 1047-1050.
44. Durr HR, Muller PE, Hiller E, Maier M, Baur A, Jansson V, Refior HJ. Malignant lymphoma of bone. Arch Orthop Trauma Surg 2002; 122: 10-16.
45. Moazzam N, Malik AA, Potti A. B-cell lymphoma mimicking multiple myeloma. Leuk Lymphoma 2002; 43: 1869-1873.
46. Lal A, Tallman MS, Soble MB et al. Hairy cell leukemia presenting as localized skeletal involvement. Leak Lymphoma 2002; 43: 2207-2211.
47. Matsushima T, Yamamoto M, Sakai K. Multiple osteolysis of peripheral extremities in a patient with adult T cell leukemia/lymphoma. Intern Med 1999; 38: 820-823.
48. Muta T, Osaki K, Yamano Y. Translocation t (9; 22) (p23; q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions. Int J Hematol 2002; 76: 344-348.
49. Muller HL, Horwitz AE, Kuhl J. Acute lymphoblastic leukemia with severe skeletal involvement: a subset of childhood leukemia with a good prognosis. Pediatr Hematol Oncol 1998; 15: 121-133.
50. Athale UH, Kaste SC, Razzouk BI, Rubnitz JE, Ribeiro RC. Skeletal manifestations of pediatric acute megakaryoblastic leukemia. J Pediatr Hematol Oncol 2002; 24: 561-565.
51. Quintini G, Barbera V, Franco V. Bone remodeling in acute myeloid leukemia. Haematologica 2001; 86: 1006.
52. Lima CS, Pinto Neto JV, da Cunha ML, Vassallo J, Cardinalli IA, De Souza CA. Osteolytic lesions as a presenting sign of acute myeloid leukemia. Haematologia (Budap) 2000; 30: 325-331.
53. Sonis ST, Fey EG. Oral complications of cancer therapy. Oncology (Huntingt) 2002; 16: 680-686.
54. Sweeney MP, Bagg J. The mouth and palliative care. Am J Hosp Palliat Care 2000; 17: 118-124.
55. Bolwell BJ, Kalaycio M, Sobecks R, Andresen S, Kuczkowski E, Bernhard L et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002; 30:587-591.
56. Ingham JM, Portenoy RK. Symptom assessment. Hematol Oncol Clin North Am 1996; 10: 21-39.
57. Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23: 239-255.
58. Pellier I, Monrigal JP, Le Moine P, Rod B, Rialland X, Granry JC. Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study. Paediatr Anaesth 1999; 9: 61-68.
59. Tamminga RY, Noordhoek M, Kroon J, Faber-Nijholt R. Ketamine anesthesia with or without diazepam premedication for bone marrow punctures in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2000; 17: 383-388.
60. Berde CB, Sethna NF. Analgesic for the treatment of pain in children. N Engl J Med 2002; 347: 1094.
61. Crock C, Olsson C, Phillips R, Chalkiadis G, Sawyer S, Ashley D et al. General anaesthesia or conscious sedation for painful procedures in childhood cancer: the family's perspective. Arch Dis Child 2003; 88: 253-257.
62. Schechter NL, Weisman SJ, Rosenblum M, Bernstein B, Conard PL. The use of oral transmucosal fentanyl citrate for painful procedures in children. Pediatrics 1995; 95: 335-339.
63. Krauss B, Green SM. Sedation and Analgesia for Procedures in Children. New Engl J Med 2000; 342: 938.
64. Wolanskyj AP, Schroeder G, Wilson PR, Habermann TM, Inwards DJ, Witzig TE. A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphoma. Clin Lymphoma 2000; 1: 154-157.
65. Peterson DE. Oral problems in supportive care: no longer an orphan topic? Support Care Cancer 2000; 8: 347-348.
66. McGuire DB. Barriers and strategies in implementation of oral care standards for cancer Patients. Support Care Cancer 2003.
67. Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest 2002; 20: 793-800.
68. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999; 7: 17-20.
69. Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari M et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study. Br J Haematol 2000; 110: 300-307.
70. Cockerham MB, Weinberger BB, Lerchie SB. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 2000; 34: 300-303.
71. Yuen KY, Woo PC, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001; 86: 554-555.
72. van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 2001; 80: 150-154.
73. Spielberger R, Stiff P, Emmanouilides C, Yanovich S, Bensinger W, Hedrick E et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning-results of a phase 2 trial. Program/Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology, Abstract 25, San Francisco, California, May 12-15, 2001.
74. Cheng KK, Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer 2001; 37:2056-2063.
75. Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B. Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant 1994; 14: 492-494.
76. Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F. Ice pops to prevent melphalan-induced stomatitis. Lancet 1996; 347: 1691-1692.
77. Rubens RD, Towlson KE, Ramirez AJ, Coltart S, Slevin ML, Terrell C, Timothy AR. Appropriate chemotherapy for palliating advanced cancer. BMJ 1992; 304: 35-40.
78. Giovannini M, Cartoni C, Cedrone M, De Gregoris C, Niscola P, Moleti ML et al. Chemioterapia palliativa in pazienti con neoplasie ematologiche in fase avanzata di malattia: esperienza dell'Unità di Cure domiciliari "Romail" presso l'Istituto d'Ematologia dell'Università "La sapienza" di Roma. (abstract). Paper presented at the Eighth Congress of the Società Italiana di Cure Palliative, Genoa, 1997.
79. Mercadante S, Fulfaro F, Casuccio A. The use of corticosteroids in home palliative care. Support Care Cancer 2001; 9: 386-389.
80. Theriault RL. Zoledronic acid (Zometa) use in bone disease. Expert Rev Anticancer Ther 2003; 3: 157-166.
81. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-3736.
82. Pistevou-Gombaki K, Eleftheriadis N, Sofroniadis I, Makris P, Kouloulias V. Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate. J Exp Clin Cancer Res 2002; 21: 429-432.
83. 153 Sm-EDTMP) targeted radiotherapy and zolendronic acid is an effective option for elderly with symptomatic refractory multiple myeloma. Proceedings of the Forty-fifth annual meeting of the American Society of Hematology, American Society of Hematology, San Diego, CA, Blood 2003; 10 (Suppl, part 1): 446a.
84. Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 2002; 6: 323-330.
85. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999; 52: 111-121.
86. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 2003; 15: 345-352.
87. Shakespeare TP, Lu JJ, Back MF, Liang S, Mukherjee RK, Wynne CJ. Patient preference for radiotherapy fractionation schedule in the palliation of painful bone metastases. J Clin Oncol 2003; 21: 2156-2162.
88. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H et al. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003; 95: 222-229.
89. Jeremic B, Shibamoto Y, Igrutinovic I. Second single 4 Gy reirradiation for painful bone metastasis. J Pain Symptom Manage 2002; 23: 26-30.
90. Hayashi S, Hoshi H, Iida T. Reirradiation with local-field radiotherapy for painful bone metastases. Radiat Med 2002; 20: 231-236.
91. Buzaid AC, Durie BGM. Management of refractory myeloma: a review. J Clin Oncol 1988; 6: 889-905.
92. Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol 2000; 176: 506-512.
93. San Miguel JF, Garcia-Sanz R. Myeloma: update on supportive care strategies. Curr Treat Options Oncol 2003; 4: 247-258.
94. Durr HR, Wegener B, Krodel A, Muller PE, Jansson V, Refior HJ. Multiple myeloma: surgery of the spine: retrospective analysis of 27 patients. Spine 2002; 27: 320-324.
95. Fourney DR, Schomer DF, Nader R, Chlan-Fourney J, Suki D, Ahrar K et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003; 98 (Suppl): 21-30.
96. Hoskin PJ, Grover A, Bhana R. Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiother Oncol 2003; 68: 175-180.
97. Chisesi T, Capnist G, Dal Fior S. Splenic irradiation in chronic lymphocytic leukemia. Eur J Haematol 1991; 46: 202-204.
98. Weinmann M, Becker G, Einsele H, Bamberg M. Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disorders. Radiother Oncol 2001; 58: 235-246.
99. van Mook WN, Fickers MM, Verschueren TA. Clinical and immunological evaluation of primary splenic irradiation in chronic lymphocytic leukemia: a study of 24 cases. Ann Hematol 2001; 80: 216-223.
100. McFarland JT, Kuzma C, Millard FE, Johnstone PA. Palliative irradiation of the spleen. Am J Clin Oncol 2003; 26: 178-183.
101. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 53: 1695-1700.
102. Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003; 4: 265-284.
103. World Health Organization. Cancer Pain Relief. World Health Organization: Geneva, 1986.
104. Boeijinga JK, van Meegen E, van den Ende R, Schook CE, Cohen AF. Lack of interaction between tramadol and coumarins. J Clin Pharmacol 1998; 38: 966-970.
105. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22: 185-192.
106. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898-2904.
107. Moryl N, Santiago-Palma J, Kornick C, Derby S, Fischberg D, Payne R, Manfredi PL. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002; 96: 325-328.
108. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999-2010.
109. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-138.
110. Mystakidou K, Befon S, Kouskouni E, Gerolymatos K, Georgaki S, Tsilika E, Vlahos L. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 2001; 21: 2225-2230.
111. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J 2004; 97: 129-134.
112. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998; 24: 425-432.
113. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F et al. Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002; 94: 832-839.
114. Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001; 22: 575-583.
115. Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manage 2000; 9: 8-15.
116. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H et al. Expert Working Group of the European Association of Palliative Care Network. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
117. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay H et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer 2001; 84: 587-593.
118. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20:348-352.
119. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002; 95:203-208.
120. Burza M, Ginobbi P, Fusco G, Laurenzi L, Tirelli W, Arcuri E. Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 1998; 149: 277-280.
121. Hill HF, Chapman CR, Kornell JA, Sullivan KM, Saeger LC, Benedetti C. Self-administration of morphine in bone marrow transplant patients reduces drug requirement. Pain 1990; 40: 121-129.
122. Coda BA, O'Sullivan B, Donaldson G, Bohl S, Chapman CR, Shen DD. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 1997; 72: 333-346.
123. Ng HN, Sim KM, Boey SK. Bone marrow harvesting using EMLA (eutectic mixture of local anaesthetics) cream, local anaesthesia and patient-controlled analgesia with alfentanil. Bone Marrow Transplant 1999; 23: 941-945.
124. Chapman CR, Donaldson GW, Jacobson RC, Hautman B. Differences among patients in opioid self-administration during bone marrow transplantation. Pain 1997; 71: 213-223.
125. Pillitteri LC, Clark RE. Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis. Bone Marrow Transplant 1998; 22: 495-498.
126. Nosari A, Anghilieri M, Cozzi P, Messina G, Morabito F, Miqueleiz S et al. Transdremal fentanyl is useful in chemotherapy-associated mucositis. Proceedings of the Forty-fourth Annual Meeting of the American Society of Hematology, American Society of Hematology (Pennsylvania) (abstract) Blood 2002; 100 (Suppl, Part 1): 387b.
127. Misefari M, D'Africa A, Sartori M, Morabito F. Transdermal transport by hydroelectrophoresis: a novel method for delivering molecules. J Biol Regal Homeost Agents 2001; 15: 381-382.
128. Portenoy RK. Adjuvant analgesic agents. Hematol Oncol Clin North Am 1996; 10: 103-119.
129. Caraceni A, Zecca E, Martini C, De Conno F. Gabapentin as adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999; 17: 441-445.
130. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-101
131. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348: 1223-1232.
132. Scaramucci L, Bongarzoni V, Niscola P, Ciafrino R, De Gregoris C, Tini V, Montanaro M. Neuropathy as dominant picture in Primary Amyloidosis: report of a case with severe clinical course. Proceedings of the seventh annual meeting of the European Haematology Association, Florence (Italy). European Haematology Association. Haematol J 2002; 3 (Suppl 1): 418.
133. Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother 2004; 5: 551-559.
134. Hautkappe M, Roizen MF, Toledano A, Roth S, Jeffries JA, Ostermeier AM. Review of the effectiveness of capsaicin for painful cutaneous disorders and neural dysfunction. Clin J Pain 1998; 14: 97-106.
135. Sawynok A Topical and peripherally acting analgesics. Pharmacol Rev 2003; 55: 1-20.
136. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004; 5: 2-19.
137. Roy S, loh HH. Effects of opioids on the immune system. Neurochem Res 1996; 21: 1375-1386.
138. Rittner HL, Brack A, Stein C. Pain and the immune system: friend or foe? Anaesthesist 2002; 51: 351-358.
139. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349: 1943-1953.
140. Sibinga Nes, Goldstein A. Opioid peptides and opioid receptors in cells of the immune system. Ann Rev Immunol 1988; 6: 219-249.
141. Makman MH. Morphine receptor in immunocytes and neurons. Adv Neuroimmunol 1994; 4: 69-82.
142. Machelska H, Stein C. Immune mechanisms in pain control. Anesth Analg 2002; 95: 1002-1008.
143. Brack A, Stein C. The role of the peripheral nervous system in immune cell recruitment. Exp Neurol 2003; 184: 44-49.
144. Machelska H, Stein C. Pain control by immune-derived opioids. Clin Exp Pharmacol Physiol 2000; 27: 533-536.
145. Brack A, Rittner HL, Machelska H, Beschmann K, Sitte N, Schafer M, Stein C. Mobilization of opioid-containing polymorphonuclear cells by hematopoietic growth factors and influence on inflammatory pain. Anesthesiology 2004; 100: 149-157.
146. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997; 121: 834-840.
147. Sacerdote P, Bianchi M, Manfredi B, Panerai AE. Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 1997; 72: 325-330.
148. Arcuri E. Can tumors act as opioid traps, mimicking opioid tolerance? J Pain Symptom Manage 1998; 16: 78-79.
149. Arcuri E, Ginobbi P, Tirelli W, Froldi R, Citro G, Santoni A. Preliminary in vivo experimental evidence on intratumoral morphine uptake. Possible clinical implications in cancer pain and opioid responsiveness. J Pain Symptom Manage 2002; 24: 1-3.
150. Fimiani C, Arcuri E, Santoni A, Rialas CM, Bilfinger TV, Peter D, Salzet B, Stefano GB. Mu3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release. Cancer Lett 1999; 146: 45-51.
151. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003; 26: 769-775.
152. Eguchi M. Recent advances in selective opioid receptor agonists and antagonists. Med Res Rev 2004; 24: 182-212.
153. Arcuri E. A project for a hospital without pain. Med Secoli 2002; 14: 233-241.